Compare Ford Motor Company (F) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Mesoblast Limited — how do they compare? Ford Motor Company trades at $13.84 (market cap $55.75B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Ford Motor Company is far larger — about 25.2× Mesoblast Limited's market cap, and Ford Motor Company pays a 4.29% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| F | MESO | |
|---|---|---|
Market Cap | $55.75B | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $17.44 | $20.96 |
52-Week Low | $11.21 | $12.88 |
Enterprise Value | $187.71B | $2.21B |
Dividend Yield | 4.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $13.865, down 1.07% on the day, with a bearish technical signal. Recent earnings show volatility, with Q2 2026 beating expectations but Q4 2025 missing. The company reported a net loss of $8.18B in 2025 despite $187.27B revenue, though operating cash flow remains strong at $21.28B. News highlights the upcoming Fathom EV truck priced at $28,350, targeting affordability in 2027.
The outlook is mixed; low P/E of 11.84 and analyst consensus price target of $16.18 suggest potential upside, but negative net income margin and high debt pose risks. Investor sentiment is cautious amid EV transition costs and competitive pressures, with 38.3% of analysts rating Buy. Key opportunities include new affordable models and strong cash flow, while execution on profitability remains critical.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
